EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia

Jorge J Castillo iD, Christian Buske iD, Judith Trotman iD, Shayna Sarosiek iD, Steven P Treon iD

American Journal of Hematology · 2023

DOI: 10.1002/ajh.26788 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Hematology, 2023. Verfasst von Jorge J Castillo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Waldenstrom Macroglobulinemia, Lymphoma, B-Cell. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bruton tyrosine kinase (BTK) inhibitors have taken a central role in the management of patients with Waldenström macroglobulinemia and are the only agents approved by the Food and Drug Administration (FDA) to treat these patients. Although associated with high rates of durable responses, unmet needs with BTK inhibitor therapy include indefinite duration therapy, high cost, scarcity of complete responses, and lower rates and shorter duration of response in patients with CXCR4 mutations. Herein, we review the data supporting the use of covalent BTK inhibitors, selected management issues, clinical trials with covalent BTK inhibitor combination regimens, and up‐and‐coming non‐covalent BTK inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Waldenstrom MacroglobulinemiaLymphoma, B-CellHumansAgammaglobulinaemia Tyrosine KinaseTyrosine Kinase InhibitorsPyrazolesPyrimidinesPiperidinesAdenineProtein Kinase Inhibitors

Substanzen

Agammaglobulinaemia Tyrosine KinaseTyrosine Kinase InhibitorsPyrazolesPyrimidinesPiperidinesAdenineProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
  • Comprehensive Cancer Center Ulm, Institute of Experimental Cancer Research, University Hospital Ulm, Ulm, Germany.
  • Department of Haematology, Concord Repatriation General Hospital, Faculty of Medicine, University of Sydney, Concord, Australia.

ORCID-Profile: Jorge J Castillo, Christian Buske, Judith Trotman, Shayna Sarosiek, Steven P Treon

Zitieren

APA

Castillo, J. J., Buske, C., Trotman, J., Sarosiek, S., & Treon, S. P. (2023). Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia. American Journal of Hematology. https://doi.org/10.1002/ajh.26788

Vancouver

Castillo JJ, Buske C, Trotman J, Sarosiek S, Treon SP. Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia. American Journal of Hematology. 2023. doi:10.1002/ajh.26788

BibTeX
@article{Castillo2023,
  author = {Castillo, Jorge J and Buske, Christian and Trotman, Judith and Sarosiek, Shayna and Treon, Steven P},
  title = {Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia},
  journal = {American Journal of Hematology},
  year = {2023},
  doi = {10.1002/ajh.26788}
}
Kostenlos starten →